Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 069: Nivolumab plus Ipilimumab in Advanced Melanoma
NCT01927419Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2013
- Primary completion
- Jul 2014
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab in melanoma, sponsored by Bristol Myers Squibb. Started Aug 2013; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01927419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01927419.